ReviewInternational journal of hematology-oncology and stem cell research2025
Evaluation of Efficacy, Safety, and Prognostic Value of Induction Chemotherapy in Patients with Acute Myeloid Leukemia: An Updated Meta-Analysis of a 5-Year Study.
Review in International journal of hematology-oncology and stem cell research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prevalence of malnutrition and the appropriateness of nutritional support among patients with hematologic malignancies: a GLIM-based study.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute Myeloid Leukemia (AML) is a type of cancer that affects the bone marrow and blood. This study aims to conduct a five-year update on induction chemotherapy's efficacy, safety, and prognostic value in patients with AML. Based on the PRISMA 2020 guidelines, a systematic search was performed on online databases for relevant studies on complete remission with incomplete hematologic response (CRi), complete remission (CR), adverse events, and overall survival. The articles obtained were observational studies that met the inclusion and exclusion criteria. The quality of the studies was assessed using the Revised Cochrane's risk-of-bias tool. The analysis was conducted using Review Manager 5.4 and R Statistical Software 3.3. Thirteen clinical trial studies, involving 1,863 participants, were included in this survey. Based on the analysis, the CRi and CR levels, where each was obtained as a whole at 9% (random effect; 95%CI 6-13%; heterogeneity; 𝜏
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.